H. Michael Shepard
59Patents
18h-index
46Co-inventors
84Inventor score
Filing activity: Jan 21, 1987 → Jul 19, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5677171A | Monoclonal antibodies directed to the HER2 receptor | Chemistry; Metallurgy | 422 | Expired |
| US5770195A | Monoclonal antibodies directed to the her2 receptor | Chemistry; Metallurgy | 253 | Expired |
| US5772997A | Monoclonal antibodies directed to the HER2 receptor | Chemistry; Metallurgy | 229 | Expired |
| US6165464A | Monoclonal antibodies directed to the HER2 receptor | Chemistry; Metallurgy | 171 | Expired |
| US5720954A | Monoclonal antibodies directed to the HER2 receptor | Chemistry; Metallurgy | 171 | Expired |
| US6015567A | HER2 extracellular domain | Human Necessities | 153 | Expired |
| US6399063B1 | Monoclonal antibodies directed to the HER2 receptor | Chemistry; Metallurgy | 153 | Expired |
| US6387371B1 | Monoclonal antibodies directed to the HER2 receptor | Chemistry; Metallurgy | 137 | Expired |
| US5837520A | Method of purification of viral vectors | Emerging Cross-Sectional Technologies | 88 | Expired |
| US6333169A | HER2 extracellular domain | Human Necessities | 79 | Expired |
| US4808402A | Method and compositions for modulating neovascularization | Human Necessities | 67 | Expired |
| US4963354A | Use of tumor necrosis factor (TNF) as an adjuvant | Human Necessities | 66 | Expired |
| US9447401B2 | PH20 polypeptide variants, formulations and uses thereof | Emerging Cross-Sectional Technologies | 30 | Active |
| US6245750A | Enzyme catalyzed therapeutic agents | Chemistry; Metallurgy | 29 | Expired |
| US9913822B2 | Combination therapy with an anti-hyaluronan agent and therapeutic agent | Chemistry; Metallurgy | 22 | Active |
| US6339151B1 | Enzyme catalyzed therapeutic agents | Chemistry; Metallurgy | 21 | Expired |
| US11066656B2 | PH20 polypeptide variants, formulations and uses thereof | Emerging Cross-Sectional Technologies | 20 | Active |
| US11041149B2 | PH20 polypeptide variants, formulations and uses thereof | Emerging Cross-Sectional Technologies | 20 | Active |
| US5851991A | Therapeutic use of the retinoblastoma susceptibility gene product | Chemistry; Metallurgy | 13 | Expired |
| US8846034B2 | Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof | Physics | 11 | Active |
| US6495553B1 | Methods and compositions for overcoming resistance to biologic and chemotherapy | Physics | 9 | Expired |
| US10865400B2 | PH20 polypeptide variants, formulations and uses thereof | Emerging Cross-Sectional Technologies | 9 | Active |
| US6159706A | Application of enzyme prodrugs as anti-infective agents | Chemistry; Metallurgy | 8 | Expired |
| US6683061B1 | Enzyme catalyzed therapeutic activation | Chemistry; Metallurgy | 8 | Expired |
| US7419968B1 | Methods for treating therapy-resistant tumors | Chemistry; Metallurgy | 5 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.